|
LEA Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer
Martin M et al. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer — First efficacy results from the LEA study. San Antonio Breast Cancer Symposium 2012; Abstract S1-7.
Dr Carey is Richardson and Marilyn Jacobs Preyer Distinguished Professor for Breast Cancer Research, Chief of the Division of Hematology and Oncology, Physician-in-Chief at the North Carolina Cancer Hospital and Associate Director for Clinical Research at the Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina.
Dr Perez is Deputy Director at Large of the Mayo Clinic Cancer Center, Group Vice Chair of the Alliance of Clinical Trials in Oncology and Serene M and Frances C Durling Professor of Medicine at the Mayo Clinic in Jacksonville, Florida.
|
